In the BioHarmony Drug Report Database

"Preview" Icon

Siponimod fumaric acid

Mayzent (siponimod fumarate) is a small molecule pharmaceutical. Siponimod fumarate was first approved as Mayzent on 2020-01-13. It has been approved in Europe to treat relapsing-remitting multiple sclerosis.

 

Trade Name

 

Mayzent
 

Common Name

 

siponimod fumarate
 

ChEMBL ID

 

CHEMBL4298150
 

Indication

 

relapsing-remitting multiple sclerosis
 

Drug Class

 

Immunomodulators

Image (chem structure or protein)

Siponimod fumaric acid structure rendering